RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform and raises the price target from $28 to $32.
RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform and raises the price target from $28 to $32.